iiinova — where your digital self keeps evolving

Tian Zhang, MD @tiansterzhangmd.bsky.social · 05/06/2026

From the @acadofinventors — First you learn, then you earn, then you return. #NAI2026

Tian Zhang, MD @tiansterzhangmd.bsky.social · 05/06/2026

Congrats to @andyzwang & all fellows inducted to the @AcadofInventors #NAI2026 tonight. Certainly recognizes a lifetime of achievement and innovation for betterment of all humans/society. @UTSW_RadOnc @UTSWMedCenter @OncoAlert @CAHON_hemonc

020

Tian Zhang, MD @tiansterzhangmd.bsky.social · 02/06/2026

@asco #ASCO26 — come for the science, stay for the people. Love our connections with friends near & far through the years, tied by common passion to improve outcomes for our patients w cancer. @oncoalert @urotoday @utswcancer @dukegucancer

020

Tian Zhang, MD @tiansterzhangmd.bsky.social · 01/06/2026

@PavlosMsaouel @UTMDAnderson w well done investigator initiated study leveraging EGFR expression in #renalmedullary — panitumumab & Abraxane. Very important life work for a rare cancer. @ASCO #ASCO26 @OncoAlert @urotoday

020

Tian Zhang, MD @tiansterzhangmd.bsky.social · 01/06/2026

@shilpaonc @ClevelandClinic w #MAINCAV results — Cabo-avelumab vs avelumab in maintenance #bladdercancer. Closed after 10% pts accrued 2/2 EV-pembro landscape changes. Valiant effort from @ALLIANCE_org. #ASCO26 @asco @oncoalert @urotoday

020

Tian Zhang, MD @tiansterzhangmd.bsky.social · 31/05/2026

@declangmurphy @PeterMacCC pushes limits of evolution of high risk #prostatecancer as we do space travel. MFS of #PROTEUS is positive &highly powered. Path CR high at 8.9%. May we keep pushing limits of #prostatecancer care. @asco #ASCO26 @OncoAlert @urotoday

020

Tian Zhang, MD @tiansterzhangmd.bsky.social · 31/05/2026

#MaryEllenTaplin @DanaFarber_GU with first plenary of the day @asco #ASCO26 — phase 3 of #PROTEUS — >2100 patients w high risk #prostatecancer, adt and apalutamide improved path CR and also a highly powered statistically significant MFS benefit. @oncoalert @urotoday @PCF_Science

120

Tian Zhang, MD @tiansterzhangmd.bsky.social · 31/05/2026

Our @utswcancer GU group out in force showing our #CTC work in #bladdercancer! The GU posters are hopping! @asco #ASCO26 @oncoalert @urotoday

000

Tian Zhang, MD @tiansterzhangmd.bsky.social · 30/05/2026

@andyzwang & I look forward to the @ASCO annual meeting each year — learning new cancer data, brainstorming for the future, gathering w friends, & enjoying child free time. Epitome of academic oncology life. Thank you @ASCO #ASCO26 @oncoalert @utswcancer

020

Tian Zhang, MD @tiansterzhangmd.bsky.social · 30/05/2026

@neerajaiims @Huntsman_GU with news splashing results of #TALAPRO3, talazoparib-enzalutamide vs enza for metastatic AR pathway sensitive HRR altered #prostatecancer. Practice changing. Concurrent @NEJM pub. Kudos to the team! 👏👏 @asco #ASCO26 @oncoalert @urotoday @oncbrothers

011

Tian Zhang, MD @tiansterzhangmd.bsky.social · 30/05/2026

@quimmateo with report of investigator initiated trial of talazoparib-enzalutamide for metastatic #prostatecancer. Even in non HRR altered dz, trend toward improving PFS. Sample size likely too small to show signif. Careful correlative work. @asco #ASCO26 @oncoalert @urotoday

010

Tian Zhang, MD @tiansterzhangmd.bsky.social · 30/05/2026

@CaPsurvivorship @DanaFarber_GU reports her many year #ARACOG trial — important objective measures for cognitive changes on darolutamide vs enzalutamide in #prostatecancer. Daro w improved cog fxn vs enza. Important work for ARPI selection. @asco #ASCO26 @oncoalert @urotoday

020

Tian Zhang, MD @tiansterzhangmd.bsky.social · 30/05/2026

@AtishChoudhury @DanaFarber_GU reports #ADREAM, a trial of de-intensification for metastatic AR sensitive #prostatecancer. Median 2 years off tx — holding tx is feasible and could be an approach in excellent responders. Sets up #LIBERTAS trial & others. #ASCO26 @oncoalert @asco

011

Tian Zhang, MD @tiansterzhangmd.bsky.social · 30/05/2026

@ASCOPres Dr Eric Small delivers a powerful presidential talk — personal tribute to his partner Dr Amy Lin who passed this yr from a rare ovarian cancer. Oncology advancements needed — for every patient. Every cancer. Everywhere. @asco #ASCO26 @oncoalert @urotoday @oncbrothers

010

Tian Zhang, MD @tiansterzhangmd.bsky.social · 30/05/2026

Opening ceremony @ASCO #ASCO26 Congrats to all the FASCO recipients today!! Saw many Duke, LDP, & GU friends — our cancer field is a great village #strongertogether 🥰 @oncoalert @urotoday @oncbrothers

000

Tian Zhang, MD @tiansterzhangmd.bsky.social · 30/05/2026

@Prof_Nick_James with #RAD-IO trial durvalumab added to chemoradiation in #bladdercancer. Great to see the evolution of treatments for bladder preservation. @asco #asco26 @oncoalert @urotoday

010

Tian Zhang, MD @tiansterzhangmd.bsky.social · 29/05/2026

Fantastic discussion @apolo_andrea @theNCI for past/present/future of nectin4. EV pembro success in #bladdercancer also sets up a new world of challenges for resistance & sequencing approaches. @asco #ASCO26 @oncoalert @urotoday

020

Tian Zhang, MD @tiansterzhangmd.bsky.social · 29/05/2026

@IyerGopa @MSKCancerCenter with phase 1 #NEXUS01 of nectin4 delivering topoisomerase inhibitor — ligand is still relevant for some EV-pembro refectory #bladdercancer w responses. @asco #ASCO26 @oncoalert @urotoday

021

Tian Zhang, MD @tiansterzhangmd.bsky.social · 29/05/2026

#YijunShen #FudanUniv (复旦大学）showing periop SHR-A2102 w adebrelimab for muscle invasive #bladdercancer. PathCR rate 48% is close to B15, good to see for the Chinese population. @asco #ASCO26 @oncoalert @urotoday

010

Tian Zhang, MD @tiansterzhangmd.bsky.social · 29/05/2026

@RonaldChenMD @KUcancercenter with full quality of life results from #AMBASSADOR trial adjuvant pembro vs placebo. More dyspnea long term but did not affect overall function. Will be monitoring for our patients on adj IO in clinic. @asco #ASCO26 @oncoalert @urotoday

020

Tian Zhang, MD @tiansterzhangmd.bsky.social · 29/05/2026

@MVossMD @MSKCancerCenter with comprehensive discussion of bone mets, ctDNA and non clear #kidneycancer. Lots to cover — Well done! #ASCO26 @asco @oncoalert @urotoday @utswcancer

010

Tian Zhang, MD @tiansterzhangmd.bsky.social · 29/05/2026

#JunruChen #HaoZeng from West China (华西）share data for non-clear cell #kidneycancer treated w new bispecific cadonilimab w axitinib. High responses in FH deficient #kidneycancer. @asco @oncoalert @urotoday @utswcancer

010

Tian Zhang, MD @tiansterzhangmd.bsky.social · 29/05/2026

@DrChoueiri presents first biomarker work from #keynote564 — ctDNA positive group only n=60 treated but poor prognosis begs question who to escalate?? And who in neg-neg group may we de-escalate treatment? @asco #ASCO26 @oncoalert @urotoday @utswcancer

021

Tian Zhang, MD @tiansterzhangmd.bsky.social · 29/05/2026

@DrRanaMcKay showcases #RADICAL results — 1st randomized radiopharmaceutical trial in #kidneycancer w bone mets, tx cabozantinib vs cabo-radium223. Closed early but important work for patients. Glad to participate @utswcancer. @asco #asco26 @oncoalert @urotoday @ALLIANCE_org

010

Tian Zhang, MD @tiansterzhangmd.bsky.social · 29/05/2026

Good morning Chicago! Kidney/bladder orals today Friday @asco #ASCO26!! Looking forward to seeing the wins for our patients with cancer, networking, and considering new trials that will make a difference. Here for all of it!! @oncoalert @utswcancer @urotoday

031

Tian Zhang, MD @tiansterzhangmd.bsky.social · 29/05/2026

000

Tian Zhang, MD @tiansterzhangmd.bsky.social · 28/05/2026

Packed and ready to go for #ASCO26! Glad to see the newest data from cancer clinical trials. This one’s for our patients. @oncoalert @asco @urotoday

010

Reposted by Tian Zhang, MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 22/01/2026

OncoAlert🚨 Coverage of DAY ONE of #AUC3 2026 #KidneyCancer Presenter Dr. Philip Pierorazio 🇺🇸 Cytoreductive nephrectomy for advanced disease: Pro Surgery for Metastatic Renal Cell Carcinoma Systemic therapy first, but… Cytoreductive nephrectomy remains a valuable tool in the management of M+RCC.

011

Reposted by Tian Zhang, MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 22/01/2026

OncoAlert🚨 Coverage of DAY ONE of #AUC3 2026 #KidneyCancer Presenter Dr. Brian Shuch 🇺🇸 Cytoreductive nephrectomy for advanced disease: Con Patients need control of their systemic disease & our better systemic therapy offers that Surgery upfront is rarely needed, and we have other ways to palliate

021

Reposted by Tian Zhang, MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 22/01/2026

OncoAlert🚨 Coverage of DAY ONE of #AUC3 2026 #KidneyCancer Presenter Dr. Pedro barata 🇺🇸 Multimodal approaches for challenging metastatic sites: Combining treatment with site-specific interventions (bone, brain, pleural disease) Certain metastatic sites matter disproportionately: Bone/brain/pleural

011

Reposted by Tian Zhang, MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 23/01/2026

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026 Urinary Tract Tumors Presenter Dr. Wesley Yip 🇺🇸 Risk stratification and treatment selection for intermediate-risk NMIBC #BladderCancer

011

Reposted by Tian Zhang, MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 23/01/2026

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026 Presenter Dr. Roger Li 🇺🇸 Personalized therapy in the post-BCG setting #BladderCancer BCG Unresponsive NMIBC defines disease no longer responding to BCG SOC for BCG exposed NMIBC should be repeat BCG

011

Reposted by Tian Zhang, MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 23/01/2026

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026 Presenter Dr. Todd Morgan 🇺🇸 Biomarkers and technology integration in NMIBC #BladderCancer Biomarker data are good-enough for clinical integration Implementation requires a workflow overhaul Realistic goal is alternation, not full replacement

011

Reposted by Tian Zhang, MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 23/01/2026

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026 Presenter Dr. David Aggen 🇺🇸 Evidence-based adjuvant approaches NMIBC #Bladder Cancer Adjuvant Therapy for High Risk Bladder Cancer Adjuvant immunotherapy is SOC in patients with high-risk disease at cystectomy

011

Reposted by Tian Zhang, MD

The OncoAlert Network 🚨 @oncoalert.bsky.social · 23/01/2026

OncoAlert🚨 Coverage of DAY TWO of #AUC3 2026 Presenter Dr. Stephanie Berg 🇺🇸 EV + pembrolizumab post adjuvant IO progression Concluding Thoughts: Defining Primary Refractory Disease & Resistance Mechanisms Is sustained PD-(L)1 inhibition necessary to improve outcomes?

021

Tian Zhang, MD @tiansterzhangmd.bsky.social · 17/10/2025

Glad to be an #ESMOAmbassador during #ESMO25 in Berlin! Here to learn the latest data for our patients and share ideas to improve future outcomes. See you in Berlin! @oncoalert.bsky.social

092

Tian Zhang, MD @tiansterzhangmd.bsky.social · 20/07/2025

#ShahneenSandhu on collaborative efforts with industry partners - how do we maximize time & effort to make industry supported IITs and large phase 3 trials for clinical development. @anzuptrials.bsky.social #ANZUP25

061

Tian Zhang, MD @tiansterzhangmd.bsky.social · 20/07/2025

@profiand.bsky.social with key insights to large trial and grant funding in Australia — trial impact, equity in diverse populations, cost effectiveness, patient advocate/consumer involvement, and feasibility @anzuptrials.bsky.social #ANZUP25

041

Tian Zhang, MD @tiansterzhangmd.bsky.social · 20/07/2025

Great kickoff to clinical trials workshop #ANZUP25 — #MelissaLeMesurier w patient perspective and #ChrisGianacas biostats on collaborative efforts for clinical trials. Same global themes for clinical trial development. @anzuptrials.bsky.social @craiggedye.bsky.social @profiand.bsky.social

042

Tian Zhang, MD @tiansterzhangmd.bsky.social · 20/07/2025

Pleasure to highlight your work with #UroToday @ravimadan.bsky.social - as we all consider how best to treat PSMA avid disease.

051

Tian Zhang, MD @tiansterzhangmd.bsky.social · 24/06/2025

Proud of our #UTSWcancer clinical research teams displaying our cancer center’s ongoing work in clinical trials @aacicancer.bsky.social #CRI25 meeting today! Clinical trials are essential to improving outcomes for our patients with cancer - here to network & learn best practices!

020

Reposted by Tian Zhang, MD

Megan Ranney MD MPH @meganranney.bsky.social · 15/06/2025

I categorically refuse to accept either of these as normal or routine. www.nytimes.com/2025/06/14/u...

nytimes.com

Like School Shootings, Political Violence Is Becoming Almost Routine

27858167

Reposted by Tian Zhang, MD

American Society of Clinical Oncology @ascocancer.bsky.social · 01/06/2025

New from #ASCO25: Final results of CheckMate-214 show that nivo + ipi continues to improve OS compared with sunitinib for previously untreated advanced RCC: dailynews.ascopubs.org/do/checkmate... #ASCODailyNews @mskcancercenter.bsky.social @tiansterzhangmd.bsky.social

031